Equities

Pulmatrix Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Pulmatrix Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.44
  • Today's Change-0.025 / -1.02%
  • Shares traded8.54k
  • 1 Year change-67.49%
  • Beta1.7107
Data delayed at least 15 minutes, as of Feb 13 2026 20:59 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.

  • Revenue in USD (TTM)3.00k
  • Net income in USD-6.22m
  • Incorporated2013
  • Employees2.00
  • Location
    Pulmatrix Inc945 CONCORD STREET, SUITE 1217FRAMINGHAM 01701United StatesUSA
  • Phone+1 (781) 357-2333
  • Fax+1 (302) 636-5454
  • Websitehttps://www.pulmatrix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
StimCell Enegetics Inc0.00-935.22k8.09m0.00---------0.0461-0.04610.00-0.07380.00-------2,062.23-844.03-----------18,037.46---17.22---------297.42------
Curanex Pharmaceuticals Inc0.00-1.30m8.12m----0.5679-----0.0497-0.04970.000.5043---------------------------142.760.00-------1,782.87------
Hi-Great Group Holding Co48.03k-64.27k8.21m--------170.94-0.0006-0.00060.0005-0.0020.72290.5559-----96.73-21.81---256.3538.7745.63-133.81-21.020.0288-------36.79--60.07------
Transcode Therapeutics Inc0.00-27.16m8.45m7.00--5.38-----354.09-354.090.001.710.00----0.00-592.26-153.21-1,387.56-219.22------------0.00------9.49------
Edesa Biotech Inc0.00-7.19m8.52m17.00--2.28-----1.35-1.350.001.740.00----0.00-82.86-103.16-99.57-123.95-----------138.680.00-------16.46------
Bioatla Inc0.00-64.71m8.86m61.00---------1.15-1.150.00-0.53130.00----0.00-165.61-49.22-317.99-57.35-------3,690.17----------16.1743.48------
Pulmatrix Inc3.00k-6.22m8.89m2.00--1.88--2,964.44-1.70-1.700.00081.300.0004----1,500.00-75.43-42.08-79.47-49.93-----207,333.30-210.36----0.00--6.96-0.264432.31--46.99--
Chemomab Therapeutics Ltd - ADR0.00-10.09m9.29m16.00--0.8276-----5.87-5.870.001.820.00----0.00-60.63---72.61--------------0.00------42.43------
Ernexa Therapeutics Inc1.00k-18.36m9.32m6.00--0.7104--9,319.69-5.32-5.320.00020.45480.0001--0.0059166.67-264.07-187.10-2,044.59-237.72100.00---1,834,000.00-3,375.91---2.730.00--755.88-50.61-105.47---19.54--
Calcimedica Inc0.00-23.06m9.43m14.00---------1.60-1.600.00-0.01880.00----0.00-148.18-58.12-194.91-64.99------------1.03------60.12---57.90--
Bolt Biotherapeutics Inc5.20m-42.68m9.50m52.00--0.296--1.83-22.27-22.272.7116.720.0596----99,903.84-48.95-46.54-58.33-52.20-----821.58-1,666.52----0.00---2.36104.508.79---39.55--
BioVie Inc0.00-17.48m9.58m13.00--0.4971-----5.13-5.130.002.550.00----0.00-72.35-260.69-79.73-454.45------------0.00------45.73------
Data as of Feb 13 2026. Currency figures normalised to Pulmatrix Inc's reporting currency: US Dollar USD

Institutional shareholders

9.74%Per cent of shares held by top holders
HolderShares% Held
Renaissance Technologies LLCas of 31 Dec 2025110.92k3.04%
BlackRock Fund Advisorsas of 31 Dec 202555.34k1.52%
SBI Securities Co., Ltd.as of 31 Dec 202555.24k1.51%
Geode Capital Management LLCas of 31 Dec 202540.94k1.12%
The Vanguard Group, Inc.as of 31 Dec 202532.29k0.88%
DRW Securities LLCas of 31 Dec 202520.51k0.56%
Vanguard Fiduciary Trust Co.as of 31 Dec 202514.79k0.41%
SSgA Funds Management, Inc.as of 31 Dec 202513.95k0.38%
Dimensional Fund Advisors LPas of 31 Dec 202510.33k0.28%
Tower Research Capital LLCas of 30 Sep 20251.44k0.04%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.